Achilles Therapeutics’ mission is to develop next-generation personalised therapies that harness the immune system to destroy cancer cells, with the potential to cure patients

These immunotherapies target clonal tumour neoantigens, protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with its proprietary bioinformatics technology, to identify clonal neoantigens specific to that patient and to develop personalised therapies. Targeting multiple clonal mutations present in every tumour cell will reduce the risk that new mutations can induce immune evasion and therapeutic resistance, as occurs with many conventional approaches.